UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8666) 8666
Book Chapter (21) 21
Magazine Article (15) 15
Dissertation (14) 14
Conference Proceeding (6) 6
Publication (5) 5
Book / eBook (2) 2
Paper (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (5456) 5456
humans (5349) 5349
life sciences & biomedicine (5011) 5011
pyridones - pharmacology (2862) 2862
male (2812) 2812
pyridones - therapeutic use (2731) 2731
animals (2394) 2394
female (2313) 2313
pyridones - administration & dosage (1567) 1567
pyridones - chemistry (1352) 1352
middle aged (1258) 1258
pharmacology & pharmacy (1239) 1239
pyridones - adverse effects (1180) 1180
aged (1164) 1164
adult (1093) 1093
administration, oral (971) 971
treatment outcome (908) 908
pyrazoles - therapeutic use (873) 873
rats (828) 828
chemistry (784) 784
abridged index medicus (733) 733
mice (721) 721
cardiovascular system & cardiology (712) 712
anticoagulants - therapeutic use (704) 704
physical sciences (683) 683
pyridones - chemical synthesis (683) 683
anticoagulants (641) 641
analysis (595) 595
dose-response relationship, drug (591) 591
milrinone (590) 590
rivaroxaban (575) 575
biochemistry & molecular biology (562) 562
pyrazoles - administration & dosage (553) 553
molecular structure (549) 549
hematology (546) 546
oncology (534) 534
atrial fibrillation - drug therapy (526) 526
pyridones - pharmacokinetics (524) 524
pyrazoles - adverse effects (523) 523
cardiac & cardiovascular systems (493) 493
dabigatran (492) 492
general & internal medicine (492) 492
structure-activity relationship (486) 486
pyridones (483) 483
apixaban (467) 467
stroke - prevention & control (463) 463
atrial fibrillation (455) 455
adolescent (447) 447
anticoagulants - administration & dosage (441) 441
anticoagulants - adverse effects (440) 440
iron chelating agents - therapeutic use (428) 428
aged, 80 and over (423) 423
deferiprone (423) 423
cell line, tumor (414) 414
research (413) 413
care and treatment (411) 411
medicine, general & internal (409) 409
hemorrhage - chemically induced (378) 378
pyridones - metabolism (372) 372
time factors (372) 372
atrial fibrillation - complications (364) 364
drug therapy (363) 363
risk factors (334) 334
warfarin - therapeutic use (333) 333
models, molecular (331) 331
drug therapy, combination (327) 327
beta-alanine - analogs & derivatives (324) 324
stroke (322) 322
peripheral vascular disease (316) 316
chemistry, medicinal (314) 314
morpholines - therapeutic use (308) 308
neurosciences & neurology (302) 302
mutation (301) 301
young adult (296) 296
child (292) 292
pirfenidone (291) 291
thiophenes - therapeutic use (289) 289
benzimidazoles - therapeutic use (288) 288
clinical trials (287) 287
retrospective studies (284) 284
in vitro techniques (281) 281
warfarin (281) 281
idiopathic pulmonary fibrosis - drug therapy (279) 279
rivaroxaban - therapeutic use (279) 279
respiratory system (268) 268
antineoplastic agents - pharmacology (263) 263
patients (262) 262
anti-inflammatory agents, non-steroidal - therapeutic use (256) 256
deferoxamine - therapeutic use (255) 255
kinetics (255) 255
medicine & public health (251) 251
cell biology (249) 249
cardiotonic agents - pharmacology (246) 246
disease models, animal (243) 243
iron - metabolism (241) 241
melanoma - drug therapy (238) 238
clinical trials as topic (237) 237
pyridones - blood (237) 237
cancer (236) 236
stroke - etiology (236) 236
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8242) 8242
German (240) 240
Japanese (176) 176
French (67) 67
Spanish (60) 60
Italian (45) 45
Chinese (36) 36
Russian (27) 27
Polish (20) 20
Portuguese (13) 13
Czech (10) 10
Dutch (8) 8
Norwegian (8) 8
Swedish (6) 6
Danish (5) 5
Hungarian (5) 5
Bulgarian (4) 4
Finnish (3) 3
Croatian (2) 2
Hebrew (2) 2
Serbian (2) 2
Korean (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 4, pp. 482 - 489
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 377, Issue 9779, pp. 1760 - 1769
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2011, Volume 364, Issue 9, pp. 806 - 817
Journal Article
Organic letters, ISSN 1523-7060, 06/2011, Volume 13, Issue 12, pp. 3278 - 3281
An inexpensive ruthenium catalyst enabled oxidative annulations of alkynes by acrylamides with ample scope, which allowed for the preparation of 2-pyridones... 
Chemistry, Organic - methods | Oxidation-Reduction | Stereoisomerism | Alkynes - chemistry | Molecular Structure | Catalysis | Pyridones - chemistry | Chemistry, Organic - economics | Ruthenium - chemistry | Pyridones - chemical synthesis | Index Medicus
Journal Article
PLoS medicine, ISSN 1549-1676, 11/2018, Volume 15, Issue 11, pp. e1002690 - e1002690
Background Cabotegravir (CAB) is a novel strand-transfer integrase inhibitor being developed for HIV treatment and prevention. CAB is formulated both as an... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | HIV Infections - prevention & control | United States | Humans | Middle Aged | Male | Pyridones - blood | Anti-HIV Agents - administration & dosage | Young Adult | Pyridones - administration & dosage | Malawi | HIV Infections - diagnosis | Brazil | Adult | Female | HIV Infections - transmission | Anti-HIV Agents - blood | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Risk Assessment | Anti-HIV Agents - adverse effects | HIV Infections - virology | Risk Factors | Treatment Outcome | Injections, Intramuscular | Anti-HIV Agents - pharmacokinetics | Adolescent | South Africa | Aged | Drug Monitoring | Delayed-Action Preparations | Pyridones - adverse effects | Prevention | Tenofovir | Usage | Safety and security measures | Analysis | Clinical trials | Pharmacokinetics | HIV infection | Drug delivery systems | Sexually transmitted diseases--STD | Funding | Risk | Population studies | Infections | Males | Randomization | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Safety | Supervision | Integrase | Medical research | Population characteristics | Health risks | Pharmacology | Injection | Medicine | Disease prevention | Infectious diseases | Men | Software | Females | Cancer | Index Medicus | STD | Sexually transmitted diseases | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Cancer chemotherapy and pharmacology, ISSN 1432-0843, 11/2014, Volume 75, Issue 1, pp. 183 - 189
To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.Eligibility criteria... 
Medicine & Public Health | MEK Inhibitor | Afuresertib | Oncology | Cancer Research | Pharmacology/Toxicology | Combination therapy | AKT Inhibitor | Trametinib | MEK inhibitor | AKT inhibitor | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Thiophenes - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Early Termination of Clinical Trials | Pyridones - administration & dosage | Multiple Myeloma - drug therapy | Neoplasms - blood | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Multiple Myeloma - enzymology | Pyrazoles - pharmacokinetics | Multiple Myeloma - blood | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Pyridones - pharmacokinetics | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasms - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Thiophenes - pharmacokinetics | Pyrazoles - administration & dosage | Pyrimidinones - pharmacokinetics | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Pyridones - therapeutic use | Pyrimidinones - administration & dosage | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Pyridones - adverse effects | Cohort Studies | Complications and side effects | Medical research | Care and treatment | Type 1 diabetes | Analysis | Gastrointestinal diseases | Multiple myeloma | Melanoma | Medicine, Experimental | Aspartate | Nausea | Tumors | Index Medicus
Journal Article
Lancet neurology, ISSN 1474-4422, 2012, Volume 11, Issue 6, pp. 503 - 511
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2012, Volume 60, Issue 8, pp. 738 - 746
Objectives This study sought to perform an indirect comparison analysis of dabigatran etexilate (2 doses), rivaroxaban, and apixaban for their relative... 
Cardiovascular | Internal Medicine | indirect comparisons | dabigatran | atrial fibrillation | rivaroxaban | apixaban | stroke prevention | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Dabigatran | Pyridones - administration & dosage | Rivaroxaban | Clinical Trials, Phase III as Topic | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Female | Benzimidazoles - adverse effects | Odds Ratio | Morpholines - adverse effects | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Stroke - etiology | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects | Stroke (Disease) | Usage | Analysis | Atrial fibrillation | Anticoagulants (Medicine) | Universities and colleges | Cardiology | Anticoagulants | Cardiac arrhythmia | Stroke | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
9.